Alzamend Neuro ALZN
NASDAQ ALZN
$1.67 -0.04 (-2.48%)
As of: Sep 10, 2026 · 9:32 AM EDT

Alzamend Neuro (ALZN) Total Liabilities (2020 - 2026)

Alzamend Neuro's (ALZN) quarterly Total Liabilities came in at $1.3 million in Q2 2026, up 112.07% year-over-year from $634761.0 in Q2 2025, and down 27.52% quarter-over-quarter from $1.9 million in Q1 2026.

Analysis

Alzamend Neuro (ALZN) Total Liabilities (2020 - 2026) Analysis & Trends

Alzamend Neuro has disclosed Total Liabilities across 7 years of filings, most recently posting $1.3 million for Q2 2026.

  • In Q2 2026, Total Liabilities rose 112.07% year-over-year to $1.3 million; the TTM figure through Apr 2026 stood at $1.3 million (up 112.07% YoY), while the FY2026 annual figure was $1.3 million, up 112.07% from the prior year.
  • Total Liabilities came in at $1.3 million for Q2 2026 at Alzamend Neuro, down from $1.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $4.6 million in Q1 2024 to a low of $466977.0 in Q1 2022.
  • Average Total Liabilities over 5 years is $1.9 million, with a median of $1.5 million recorded in 2022.
  • Year-over-year, Total Liabilities soared 465.87% in 2023 and sank 84.11% in 2025.
  • Over 5 years, Total Liabilities stood at $1.6 million in 2022, then jumped by 123.89% to $3.7 million in 2023, then sank by 65.77% to $1.3 million in 2024, then sank by 42.82% to $717488.0 in 2025, then soared by 87.62% to $1.3 million in 2026.
  • Per Business Quant data, the three most recent Total Liabilities figures were $1.3 million in Q2 2026, $1.9 million in Q1 2026, and $717488.0 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Liabilities (Qtr)
1 Amgen 207.68 Bn 193.69 Bn 7.24 Bn 83.95 Bn
2 Gilead Sciences 178.73 Bn 175.55 Bn 6.22 Bn 37.53 Bn
3 Vertex Pharmaceuticals 131.05 Bn 123.20 Bn 2.84 Bn 7.18 Bn
4 Regeneron Pharmaceuticals 81.79 Bn 73.80 Bn 3.93 Bn 10.02 Bn
5 Argenx Se 60.99 Bn 55.81 Bn 1.37 Bn 1.62 Bn
6 Moderna 53.41 Bn 48.27 Bn 52.00 Mn 4.20 Bn
7 Alnylam Pharmaceuticals 33.41 Bn 30.10 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.72 Bn 30.43 Bn 1.96 Bn 13.24 Bn
9 Roivant Sciences 29.53 Bn 29.53 Bn 1.16 Mn 384.62 Mn
10 Alzamend Neuro 5.57 Mn 5.57 Mn - 1.35 Mn
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2026 1.35 Mn
Jan 31, 2026 1.86 Mn
Oct 31, 2025 717,488.00
Jul 31, 2025 983,311.00
Apr 30, 2025 634,761.00
Jan 31, 2025 725,851.00
Oct 31, 2024 1.25 Mn
Jul 31, 2024 2.88 Mn
Apr 30, 2024 3.23 Mn
Jan 31, 2024 4.57 Mn
Oct 31, 2023 3.67 Mn
Jul 31, 2023 2.74 Mn
Apr 30, 2023 2.87 Mn
Jan 31, 2023 2.64 Mn
Oct 31, 2022 1.64 Mn
Jul 31, 2022 1.03 Mn
Apr 30, 2022 1.16 Mn
Jan 31, 2022 466,977.00
Oct 31, 2021 1.48 Mn
Jul 31, 2021 1.47 Mn